569 related articles for article (PubMed ID: 24291281)
1. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.
Ky B; Putt M; Sawaya H; French B; Januzzi JL; Sebag IA; Plana JC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
J Am Coll Cardiol; 2014 Mar; 63(8):809-16. PubMed ID: 24291281
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab.
Putt M; Hahn VS; Januzzi JL; Sawaya H; Sebag IA; Plana JC; Picard MH; Carver JR; Halpern EF; Kuter I; Passeri J; Cohen V; Banchs J; Martin RP; Gerszten RE; Scherrer-Crosbie M; Ky B
Clin Chem; 2015 Sep; 61(9):1164-72. PubMed ID: 26220066
[TBL] [Abstract][Full Text] [Related]
3. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Tan TC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
Circ Cardiovasc Imaging; 2012 Sep; 5(5):596-603. PubMed ID: 22744937
[TBL] [Abstract][Full Text] [Related]
4. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
[TBL] [Abstract][Full Text] [Related]
5. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients.
Romano S; Fratini S; Ricevuto E; Procaccini V; Stifano G; Mancini M; Di Mauro M; Ficorella C; Penco M
Br J Cancer; 2011 Nov; 105(11):1663-8. PubMed ID: 22068815
[TBL] [Abstract][Full Text] [Related]
6. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
[TBL] [Abstract][Full Text] [Related]
7. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
8. Cardiac biomarkers, cardiotoxicity, and active collaboration: is this the final frontier or the wave we should catch?
Lenihan DJ
J Am Coll Cardiol; 2014 Mar; 63(8):817-8. PubMed ID: 24291278
[No Abstract] [Full Text] [Related]
9. Identification of Clinical and Laboratory Variables Associated with Cardiotoxicity Events Due to Doxorubicin in Breast Cancer Patients: A 1-Year Follow-Up Study.
Simões R; Silva LM; de Oliveira AN; Alves MT; Pestana RMC; de Souza IDP; Oliveira HHM; Soares CE; Sabino AP; Gomes KB
Cardiovasc Toxicol; 2021 Feb; 21(2):106-114. PubMed ID: 32844368
[TBL] [Abstract][Full Text] [Related]
10. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.
Zardavas D; Suter TM; Van Veldhuisen DJ; Steinseifer J; Noe J; Lauer S; Al-Sakaff N; Piccart-Gebhart MJ; de Azambuja E
J Clin Oncol; 2017 Mar; 35(8):878-884. PubMed ID: 28199174
[TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial.
Rüger AM; Schneeweiss A; Seiler S; Tesch H; van Mackelenbergh M; Marmé F; Lübbe K; Sinn B; Karn T; Stickeler E; Müller V; Schem C; Denkert C; Fasching PA; Nekljudova V; Garfias-Macedo T; Hasenfuß G; Haverkamp W; Loibl S; von Haehling S
J Am Heart Assoc; 2020 Dec; 9(23):e018143. PubMed ID: 33191846
[TBL] [Abstract][Full Text] [Related]
12. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Perik PJ; Lub-De Hooge MN; Gietema JA; van der Graaf WT; de Korte MA; Jonkman S; Kosterink JG; van Veldhuisen DJ; Sleijfer DT; Jager PL; de Vries EG
J Clin Oncol; 2006 May; 24(15):2276-82. PubMed ID: 16710024
[TBL] [Abstract][Full Text] [Related]
13. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series.
Cil T; Kaplan AM; Altintas A; Akin AM; Alan S; Isikdogan A
Clin Drug Investig; 2009; 29(2):131-7. PubMed ID: 19133708
[TBL] [Abstract][Full Text] [Related]
14. New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide.
van Boxtel W; Bulten BF; Mavinkurve-Groothuis AM; Bellersen L; Mandigers CM; Joosten LA; Kapusta L; de Geus-Oei LF; van Laarhoven HW
Biomarkers; 2015 Mar; 20(2):143-8. PubMed ID: 25980453
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.
Cardinale D; Colombo A; Torrisi R; Sandri MT; Civelli M; Salvatici M; Lamantia G; Colombo N; Cortinovis S; Dessanai MA; Nolè F; Veglia F; Cipolla CM
J Clin Oncol; 2010 Sep; 28(25):3910-6. PubMed ID: 20679614
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy.
Huang G; Zhai J; Huang X; Zheng D
Medicine (Baltimore); 2018 Sep; 97(38):e12447. PubMed ID: 30235730
[TBL] [Abstract][Full Text] [Related]
17. Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer.
Goel S; Simes RJ; Beith JM
Asia Pac J Clin Oncol; 2011 Sep; 7(3):276-80. PubMed ID: 21884439
[TBL] [Abstract][Full Text] [Related]
18. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients.
Blancas I; Martín-Pérez FJ; Garrido JM; Rodríguez-Serrano F
Breast; 2020 Dec; 54():106-113. PubMed ID: 32977298
[TBL] [Abstract][Full Text] [Related]
19. [Troponin I and B-type Natriuretic Peptide (BNP) as biomarkers for the prediction of cardiotoxicity in patients with breast cancer treated with adjuvant anthracyclines and trastuzumab].
Pistillucci G; Ciorra AA; Sciacca V; Raponi M; Rossi R; Veltri E
Clin Ter; 2015; 166(1):e67-71. PubMed ID: 25756270
[TBL] [Abstract][Full Text] [Related]
20. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients.
Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Cohen V; Gosavi S; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
Am J Cardiol; 2011 May; 107(9):1375-80. PubMed ID: 21371685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
